

(19) World Intellectual Property Organization
International Bureau



09 JUL 2004



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057708 A2

- (51) International Patent Classification⁷: C07K (74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).
- (21) International Application Number: PCT/GB03/00078
- (22) International Filing Date: 10 January 2003 (10.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0200689.8 10 January 2002 (10.01.2002) GB
- (71) Applicant (for all designated States except US): **NEWCASTLE UNIVERSITY VENTURES LIMITED** [GB/GB]; Central Square South, Orchard Street, Newcastle Upon Tyne, NE1 3XX (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GOKCE, Isa** [TR/TR]; Gaziosmanpasa Universitesi, Fen Edebiyat Fakultesi Kimya Bolumu, 60240 Tokat (TR). **ANDERLUH, Gregor** [SI/SI]; Department of Biology, Biotechnical Faculty, University of Ljubljana, Vecna pot 111, 1000 Ljubljana (SI). **LAKEY, Jeremy, Hugh** [GB/GB]; School of Cell and Molecular Biosciences, The Medical School, The University of Newcastle-upon-Tyne NE2 4HH (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FUSION PROTEINS

(57) Abstract: The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or purification systems. The present inventors have found that the To1AIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell. In one aspect of the invention, a To1AIII domain or a functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and a non-To1A polypeptide is located towards the C-terminus of the fusion polypeptide.

BEST AVAILABLE COPY

FUSION PROTEINS

The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or purification systems.

Purified proteins are required for several applications. However, the isolation of pure proteins, in sufficient quantities, is sometimes problematic. For protein function studies, large amounts of a protein of interest (for example, a mutated protein) are often needed. Various expression systems have been used for heterologous production of proteins. *Escherichia coli* (*E. coli*) is still the most common host despite huge advances in the area of protein expression in the last ten years in other hosts. *E. coli* is popular because expressing proteins in the bacterium is relatively simple and a vast amount of knowledge about bacterium itself exists, and (sometimes most importantly) because of the low costs associated with production.

Proteins can be expressed in *E. coli* either directly or as fusions (of a "fusion partner" and a protein or polypeptide), also known as fusion proteins. The purpose of fusion partners is to provide affinity tags (e.g. His_n tag, glutathione-S-transferase, cellulose binding domain, intein tags), to make proteins more soluble (e.g. glutathione-S-transferase), to enable formation of disulphide bonds (e.g. thioredoxin), or to export fused proteins to the periplasm where conditions for the formation of disulphide bonds are more favourable (e.g. DsbA and DsbC). Proteins used as fusion partners are normally small (less than 30 kDa).

TolA is a periplasmic protein involved in (1) maintaining the integrity of the inner membrane and (2) the uptake of colicins and bacteriophages. The first function is evidenced by the increased outer membrane instability (e.g. SDS sensitivity) of TolA mutants. This function has been shown by various authors and may depend upon the interaction with the TolB protein (Levengood-Freyermuth *et al.*, 1993, *J. Bacteriol.* **175**: 222-228; Wan & Baneyx, 1998, *Protein Expression & Purification* **14**: 13-22). Wan and Banex (1998, *supra*) have demonstrated that co-expression of the C-terminal TolAIII domain of TolA (see below) facilitates the recovery of periplasmic recombinant proteins into the growth medium of *E. coli*, confirming that overproduction of the TolAIII domain

disrupts the outer membrane and causes periplasmic proteins to leach into the growth medium.

The second function of TolA is based upon the use of TolA as a receptor by phage proteins (Lubkowski, J. *et al.*, 1999, *Structure With Folding & Design* 7: 711-722) and colicins (Gokce, I. *et al.*, 2000, *J. Mol. Biol.* 304: 621-632). This has been revealed both by the phage/colicin resistance of tolA mutants and by direct demonstration of the tolA -protein interactions by physical methods. TolA is composed of three domains. A short N-terminal domain is composed of a single transmembrane helix, which anchors TolA in the inner membrane. The second, largest domain is polar and mainly α -helical. A C-terminal domain III (TolAIII) is small and composed of 92 amino acids. Its 3D structure was recently solved in a complex with N1 domain of minor coat gene 3 protein of Ff filamentous bacteriophage (Holliger, P. *et al.*, 1999, *J. Mol. Biol.* 288: 649-657). It is tightly folded into a slightly elongated protein with the aid of one disulphide bond (Figure 1).

Lubkowski *et al.* (1999; *supra*) disclose a fusion protein comprising residues 1-86 (the N1 domain) of the filamentous Ff bacteriophage minor coat gene 3 protein g3p towards the N-terminus and residues 295-425 (including the TolAIII domain) of TolA, a coreceptor of g3p, towards the C-terminus, and a C-terminal Ala₃His₆ (SEQ ID NO: 1) tail. The fusion protein was used by Lubkowski *et al.* to elucidate the crystal structure of a complex formed between the g3p N1 and TolAIII domains.

Various homologues of the TolA protein are known, for example from *E. coli* (SwissProt Acc. No. P19934), *Salmonella* species (for example Genbank Acc. Nos gi16764117 and gi1675986, *Pectobacterium* species (for example Genbank Acc. No. gi16116636) and *Haemophilus* species (for example Genbank Acc. No. gi2126342).

The present inventors have found that the TolAIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell.

According to the present invention, there is provided a fusion polypeptide for expression in

a host cell comprising a TolAIII domain or a functional homologue, fragment, or derivative thereof and a non-TolA polypeptide, wherein the TolAIII domain or functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and the non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide.

As used herein, the terms “polypeptide” and “protein” are synonymous and refer to a sequence of two or more linked amino acid residues.

The TolAIII domain, when located towards the N-terminus of a fusion polypeptide, has been shown by the present inventors to facilitate higher than expected levels of the TolAIII fusion polypeptide expression in a host cell. The TolAIII domain fusions will be useful, for example, for obtaining purified protein and polypeptide partners and/or for studying the properties of these partners.

The fusion polypeptide may further comprise a signal peptide. This will allow the fusion polypeptide to be targeted to a specific intra- or extra-cellular location. The signal peptide may be located at or near the N-terminus of the fusion polypeptide. The signal peptide may be cleaved from the fusion polypeptide during the targetting process.

If the fusion polypeptide has the basic structure: N terminus – TolAIII - Protein partner – C terminus, it may be expected that it will be expressed in high yields in the cytoplasm. If, however, the fusion polypeptide has the basic structure: N terminus - Signal peptide - TolAIII - Protein partner – C terminus, the signal peptide may be used to target the construct to a non-cytoplasmic location. For example, in *E. coli* expression systems the ribose-binding-protein signal peptide (for example, the *E. coli* ribose-binding-protein signal peptide [SEQ ID NO: 2]) may be used to target a fusion protein to the periplasm. Signal peptides which may be suitable for use in the present invention conform to a set of general rules which are described in Von Heijne, G. 1985, J. Mol. Biol. 184 (1): 99-105.

The TolAIII domain or functional homologue, fragment, or derivative thereof may be codon-optimised for expression in the host cell.

The fusion polypeptide may further comprise a linker between the TolAIII domain or functional homologue, fragment, or derivative thereof and the non-TolA polypeptide. The linker may provide a physical separation between the TolAIII domain or functional homologue, fragment, or derivative thereof and the non-TolA polypeptide or may be functional. The linker may comprise at least one cleavage site for an endopeptidase. For example, the cleavage site may comprise the amino acid sequence DDDDK (SEQ ID NO: 3; for enterokinase) and/or LVPR (SEQ ID NO: 4; for thrombin) and/or IEGR (SEQ ID NO: 5; for factor Xa).

In one embodiment, the fusion polypeptide according to invention may further comprise an affinity purification tag. The affinity purification tag may be located at or near the N-terminus of the fusion polypeptide. For example, the affinity purification tag is an N-terminal His_n tag, with n=4, 5, 6, 7, 8, 9 or 10 (SEQ ID NOs: 6 – 12, respectively; preferably n=6 [SEQ ID NO: 8]), optionally with the His_n tag linked to the fusion polypeptide by one or more Ser residues (preferably two). The affinity purification tag will provide one means for immobilising the fusion polypeptide, for example as a step in purification.

In one embodiment, the fusion polypeptide comprises a signal peptide at the N-terminus and an affinity purification tag near the N-terminus. If the signal peptide is cleaved from the fusion polypeptide during targeting, then the affinity purification tag may be located at or nearer to the new N-terminus of the fusion protein.

Preferably, the TolAIII domain consists of amino acid residues 329-421 (SEQ ID NO: 13) of *Escherichia coli* TolA (SwissProt Acc. No. P19934).

The host cell may be bacterial (for example, *Escherichia coli*).

The non-TolA polypeptide of the fusion polypeptide may be human BCL-XL (SWISSPROT Accession No. B47537). The fusion polypeptide with human BCL-XL may comprise the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 15. As shown in Example 2 below, large amounts of BCL-XL (an important protein in apoptosis and cancer

research) can be generated by expression as a TolAIII fusion polypeptide.

Further provided according to the present invention is a DNA molecule encoding the fusion polypeptide as defined above. The mRNA properties of the DNA molecule when transcribed may be optimised for expression in the host cell.

Also provided is an expression vector comprising the DNA molecule as defined above for expression of the fusion polypeptide of the invention. The expression vector may have an inducible promoter (for example, the IPTG-inducible T7 promotor) which drives expression of the fusion polypeptide. The expression vector may also have an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).

In another aspect of the invention there is provided a cloning vector for producing the expression vector as defined above, comprising DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof upstream or downstream from a cloning site which allows in-frame insertion of DNA encoding a non-TolA polypeptide. The cloning vector may further comprise DNA encoding at least one cleavage site (for example, the amino acid sequence DDDDK [SEQ ID NO: 3] and/or LVPR [SEQ ID NO: 4] and/or IEGR [SEQ ID NO: 5]) for an endopeptidase, the cleavage site located between the DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof and the cloning site. The cloning site may comprise at least one restriction endonuclease (for example, *Bam*HI and/or *Kpn*I) target sequence. The cloning vector may further comprise DNA encoding an affinity purification tag as defined above. The cloning vector may further comprise an inducible promoter (for example, the IPTG-inducible T7 promotor) and/or DNA encoding an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).

For example, the cloning vector may have the structure of pTolE, pTolT or pTolX (as shown in Figure 2 with reference to the description).

Also provided is the use of the TolAIII domain or functional homologue, fragment, or

derivative thereof for production of a fusion polypeptide as defined above.

Further provided is the use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of the DNA molecule as defined above.

Yet further provided is the use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of an expression vector as defined above.

Also provided is the use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of a cloning vector as defined above.

In one aspect there is provided a host cell containing the DNA as defined above and/or the expression vector as defined above and/or the cloning vector as defined above.

In another aspect there is provided the use of the fusion polypeptide as defined above for immobilisation of the non-TolA polypeptide, comprising the step of:
binding the fusion polypeptide to a TolA binding polypeptide (eg. the TolA-recognition site of colicin N [Gokce *et al.*, 2000, *supra*] or other colicins, the TolA binding region of bacteriophage g3p-D1 protein [Riechmann & Holliger, 1997, *Cell* 90: 351-360], or the TolA binding region of TolB or other Tol proteins).

It is known that TolAIII interacts specifically with several naturally occurring proteins such as colicins, phage proteins and other Tol proteins. This range of existing binding partners makes the over expression of TolAIII fusion proteins of particular utility since these proteins may be used in purification or immobilisation technologies. The TolAIII domain therefore not only drives high expression of the fusion polypeptide but also provides an affinity tag for purification, immobilisation or analysis of the fusion polypeptide. The TolAIII binding proteins (or binding polypeptide domains thereof) could be used to provide binding sites for the TolAIII fusions (as in Figure 6). Protein chips could be made using these TolAIII binding proteins which then bind the TolAIII fusion proteins. This provides a way to immobilise a wide variety of proteins on the surface using the TolAIII fusion as the common interaction.

Alternatively, the fusion polypeptide comprising an affinity tag as defined above may be used for immobilisation of the non-TolA polypeptide, comprising the step of:
binding the affinity tag of the fusion polypeptide to a binding moiety.

Also provided is the use of the fusion polypeptide as defined above for purification and isolation of the non-TolA polypeptide, comprising the steps of:

- (i) binding the fusion polypeptide to a TolA binding polypeptide (eg. the TolA-recognition site of colicin N or other colicins, the TolA binding region of bacteriophage g3p-D1 protein, or the TolA binding region of TolB or other Tol proteins);
- (ii) cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and
- (iii) separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

In an alternative embodiment, the fusion polypeptide comprising an affinity tag may be used for purification and isolation of the non-TolA polypeptide, comprising the steps of:

- (i) binding the affinity tag of the fusion polypeptide to a binding moiety;
- (ii) cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and
- (iii) separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

The fusion polypeptide as disclosed herein may be used for studying interaction properties of the non-TolA polypeptide or the fusion polypeptide, for example self-interaction, interaction with another molecule, or interaction with a physical stimulus.

Also provided is a method for high expression of a polypeptide as a fusion polypeptide in a host cell, comprising the step of expressing the polypeptide as a fusion polypeptide as defined above in a host cell. Levels of expression of a polypeptide as a fusion protein defined herein will be high relative to levels of expression of a polypeptide not linked to the TolAIII domain.

The invention will be further described with reference to the accompanying figures. Of the figures:

Figure 1: (Prior art) Shows the structure and sequence of third domain of TolA. The model is from the crystal structure of complex between TolAIII and N1 domain of minor coat gene 3 protein from filamentous bacteriophage (Holliger *et al.*, 1999, *supra*). Disulphide bond is labelled black. Residues 333-421 were resolved in the model;

Figure 2: Shows pTol expression vectors. pTol vectors are T7 based expression vectors derived from pET8c. The tagged TolAIII region, depicted generically in the middle panel sequence (SEQ ID NO: 16), is inserted in between XhoI and MluI sites. His₆-Ser₂ linker (SEQ ID NO: 17) precedes the TolA gene for domain III, coding for TolA amino acids 329-421 (SEQ ID NO: 13). Short flexible part (Gly-Gly-Gly-Ser; SEQ ID NO: 18) then follows and the cleavage site for endopeptidases composed of four or five amino acids (denoted by X in middle panel and underlined in bottom panel). The bottom panel shows the DNA sequences (SEQ ID NOs: 19-21, respectively) and encoded amino acid residues (SEQ ID NOs: 22-24, respectively) of the cleavage/cloning site of the tagged TolAIII region of pTolE, pTolT and pTolX. The cleavage site is denoted by an arrow. Stop codons are shown as asterisks;

Figure 3: Characterization of TolAIII expression. A: SDS-PAGE of expressed TolAIII from using three different vectors. Lane 1, pTolT uninduced; lane 2, pTolX; lane 3, pTolE; lane 4, pTolT. B: Growth curve of bacteria with pTolT. Uninduced (solid squares) sample, induced (open squares) sample. 1 mM IPTG was added to induce sample at the time denoted by an arrow. C: SDS-PAGE of fractionation of bacteria after expression of TolAIII from pTolT. Lane 1, uninduced sample; lane 2, induced bacteria; lane 3, periplasmic fraction; lane 4, cytoplasmic fraction; lane 5, insoluble (membrane + inclusion bodies) fraction. M, molecular weight marker;

Figure 4: Expression of different proteins in E.coli using pTol system. A: Expression of fusion of TolAIII with prokaryotic proteins. Lane 1, colicin N 40-76; lane 2, $\Delta 10$ T-

domain colicin N; lane 3, R-domain colicin N. Bottom panel presents an estimation of proportion of expressed protein in bacterial cells as determined from scanned gels with the software package Tina. Values reported represent average of estimation from 5-11 colonies \pm SD. B: Expression of fusion of TolAIII with eukaryotic proteins. Lane 1, PDK2; lane 2, NBD1 domain; lane 3, EqtII; lane 4, PLA₂. Values in bottom are average of estimation from 4-8 colonies \pm SD. C: Expression of fusion of TolAIII with membrane proteins. Lane 1, uninduced pTolT; lane 2, induced BcrC; lane 3, induced TM1. The position where expressed BcrC and TM1 should appear on the gel is denoted by an asterisk and circle, respectively. M, molecular weight marker; C, control of bacterial cells from uninduced sample of pTolT;

Figure 5: Purification of R-domain of colicin N. Lane 1, uninduced cells containing pTolT-Rdomain vector; lane 2, induced cells; lane 3, bacterial cytoplasmic fraction; lane 4, flowthrough of Ni-NTA chromatography; lane 5, purified fusion TolT-Rdomain proteins; lane 6, purified R domain after cleavage and ion-exchange chromatography;

Figure 6: Depicts diagrammatically various uses of a His-tagged fusion protein. (I) A TolIIIA ("Tol") fusion partner (depicted as an oval) with a His₆ (H6) affinity tag (depicted as a rectangle) is attached to a non-TolAIII polypeptide (depicted as a circle). (II) To obtain purified non-TolAIII polypeptide, it may be removed from the fusion protein by endopeptidase cleavage (depicted as a lightning bolt) and purified. For interaction studies and the creation of protein arrays, the fusion protein may be immobilised in a variety of ways e.g. to a Nickel Chelate substrate via the His₆ tag or (III) (as shown) using an immobilised tag made from all or part of a recognised TolAIII binding protein from bacteria or phage, allowing the non-TolAIII polypeptide (or the entire fusion) to be available for interaction studies. The interaction between the non TolA-III polypeptide and a molecule that recognises it (protein, DNA, carbohydrate, lipid etc) is shown in (IV). The partner is shown as a half circle;

Figure 7: Shows a circular plasmid map of a construct used to produce a Tol-A-III and BCL-XL fusion polypeptide;

Figure 8: Shows an SDS-PAGE of expressed TolAIII-BCLXL fusion protein. Lane 1, whole cell pellet, Lane 2, supernatant after ultra centrifugation, lane 3, column wash with resuspension buffer, lane 4, wash with 50 mM imidazole, lane 5, molecular weight marker, lane 6, elution with 300 mM imidazole; and

Figure 9: Shows an SDS-PAGE of thrombin-cleaved TolAIII-BCLXL fusion protein. Lane 1, whole fusion protein, Lane 2, and 4 fusion protein after thrombin cleavage, lane 3, molecular weight marker, lane 5, flow through the column, lane 6, wash, lane 7, wash with 2M NaCl, lane 8, elution with 300 mM imidazole.

EXPERIMENTAL

In our laboratory we first prepared fusion proteins between domain III of periplasmic TolA protein (TolAIII) and T domain of colicin N. Huge amounts of fusion protein was isolated when TolAIII was at the N-terminus and T-domain at the C-terminus. On the other hand, when the colicin N domain was the N-terminal partner no expression of fusion protein was obtained.

Here we describe cloning of pTol vectors that use TolAIII as a fusion partner at the N-terminal part of expressed fusion protein. We show that levels of expression of various fusion proteins are around 20 % of total bacterial proteins and we were able to purify 50-90 mg of fusions per l of bacterial broth. We prepared different components of colicin N by the use of this system.

In Example 1, several proteins were expressed using the system. These were different parts and domains of colicin N (TolA binding box (peptide of amino acids 40-76), deletion mutant of T-domain ($\Delta 10$) and R domain), representing prokaryotic proteins. Human phospholipase A₂, pore-forming protein from sea anemone equinatoxin II, nucleotide binding domain 1 (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) and human mitochondrial pyruvate dehydrogenase kinase 2 (PDK2) were examples of eukaryotic proteins. Transmembrane proteins were represented by BcrC, a component of bacitracin resistance system from *Bacillus licheniformis*, and transmembrane domain 1 (TM1) of human CFTR. The expression of BCL-XL, an important protein in apoptosis and cancer research, as a TolAIII fusion polypeptide is shown in Example 2.

For Example 1, in all cases except for two membrane proteins the yields of fusion protein were higher than the individual proteins. The expression of small peptides and soluble proteins was consistently good. More difficult targets were also chosen. The membrane proteins did not express at all. The human PLA, PDK₂ and equinatoxin expressed well but as in the case of the individual proteins much ends up as insoluble fraction. PLA has many SS bonds and PDK has consistently resisted soluble expression in other systems. The TolAIII was not able to overcome the insoluble behaviour of these fusion partners but their

recovery from inclusion bodies is still possible. In Example 2, large amounts of BCL-XL were expressed.

MATERIALS AND METHODS

Example 1:

Cloning of pTol vectors:

The original vector used in cloning was a derivative of pET3c (Novagen) termed pET8c. The pET8c vector was constructed by adding to the pET3c vector nucleotides encoding methionine followed by six histidine and two serine residues downstream of the cloning site (Politou, A.S. *et al.*, 1994, *Biochemistry* 33(15): 4730-4737). The pET8c vector was used for an expression of fusion between domain III of TolA (amino acids 329-421; SEQ ID NO: 13) protein and T domain of colicin N. It is T7 based expression vector with *bla* gene, providing ampicillin selection. The fusion protein contains a methionine followed by six histidines and two serines at the N-terminal part. This linker enables easy purification using Ni-chelate affinity chromatography. The fusion partners were linked together via *Bam*HI site. The C-terminal end of the fusion was cloned via *Mlu*I site. The T-domain gene was removed from the vector by restricting it with *Bam*HI and *Mlu*I. An adaptor sequence was then ligated into the vector. It was composed in such a way that it removed the *Bam*HI site within the flexible linker, but introduced a new *Bam*HI site just after the cleavage sequence for endopeptidases (Figure 2). In this way fused partners can be cloned in pTol vector via *Bam*HI or *Kpn*I site, leaving a tag of two (Gly-Ser; SEQ ID NO: 25) or four (Gly-Ser-Gly-Thr; SEQ ID NO: 26) amino acids, respectively, at the N-terminus (see Figure 2).

The linker between TolAIII and fused partner is, therefore, composed of flexible part (Gly-Gly-Gly-Ser; SEQ ID NO: 18) and cleavage sequence for endopeptidases (enterokinase, factor Xa or thrombin) (Figure 2). The oligonucleotides (all oligonucleotides from MWG Biotech) with the following sequences were used as an adaptors:

E(+) (5'-GATCTGATGATGACGATAAAGGATCCGGTACCTGATGAA-3'; SEQ ID NO: 27) and

E(-) (5'-CGCGTTCATCAGGTACCGGATCCTTTATCGTCATCATCA-3'; SEQ ID NO: 28) for enterokinase;
 X(+) (5'-GATCTATTGAAGGTCGCGGATCCGGTACCTGATGAA-3'; SEQ ID NO: 29) and
 X(-) (5'-CGCGTTCATCAGGTACCGGATCCGCGACCTTCAATA-3'; SEQ ID NO: 30) for factor Xa;
 T(+) (5'-GATCTCTGGTTCCGCGCGGATCCGGTACCTGATGAA-3'; SEQ ID NO: 31) and T(-) (5'-CGCGTTCATCAGGTACCGGATCCGCGCGGAACCAGA-3'; SEQ ID NO: 32) for thrombin cleavage sites.

Newly cloned vectors were named pTolE, pTolX, pTolT and they comprise cleavage sequences for enterokinase, factor Xa, and thrombin, respectively. Fusion partners used to test the system were cloned into the pTol vectors via *Bam*HI and *Mlu*I sites. If the nucleic acid sequence coding for a particular protein contained internal *Bam*HI site, a *Kpn*I site was used instead. Nine different proteins were used to test the system (Table 1). Coding sequences were amplified by PCR. Reaction mixture contained (in 100 µl total volume): 10 µl of 10 X reaction buffer supplied by the producer, 2 µl of 100 mM MgSO₄, 4 µl of dNTP mix (200 µM final concentration), 100 pmol of each oligonucleotide, approximately 20 ng of target DNA and 1 Unit of Vent DNA polymerase (New England BioLabs). Target DNA was obtained either from DNA cloned into plasmids (e.g. colicin sequences were from the plasmid pCHAP4 [Pugsley, A.P., 1984, Mol. Microbiol. 1: 317-325], equinatoxin sequences were from an equinatoxin-containing plasmid described in Anderluh G. *et al.*, 1996, Biochem. Biophys. Res. Commun. 220: 437-42, and BcrC sequences were from an BcrC-containing plasmid described in Podlesek, Z. *et al.*, 1995, Mol. Microbiol. 16: 969-976) or via direct PCR or RT-PCR from the host organism. The resulting DNA was sequenced after cloning into pTol to ensure that it corresponded to precisely to the section of the published sequence shown in the table. Typically the following cycles were used: 10 min at 97°C; 30 cycles, each composed of 2 min denaturation at 97°C, 1 min of annealing at 58°C, 1 min of extension at 72°C; 7 min at 72°C and soak at 10°C. PCR fragments were purified using commercial kits (Qiagen) and restricted by an appropriate restriction endonucleases. Restricted fragments were cloned into pre-cleaved pTol vector. The correct nucleotide sequence of the fusion protein was verified by sequencing.

Table 1: Proteins used to test pTol fusion expression system:

Protein	Amino acids / SwissProt Acc. No.	Mw ^a	Plasmid	Cloning ^b Site	Oligos for PCR ^d
Colicin N 40-76 (SEQ ID NO: 33)	40-76 / P08083	16038	pTolE, T, X	<i>Bam</i> HI	1,2
Colicin N Δ10 T-domain (SEQ ID NO: 34)	11-90 / P08083	18567	pTolT	<i>Bam</i> HI	3,4
Colicin N R domain (SEQ ID NO: 35)	67-183 / P08083	24667	pTolT	<i>Bam</i> HI	5,6
Human PLA ₂ (SEQ ID NO: 36)	21-144 / P14555 & NP_000291.1 ^c	25810	pTolT	<i>Kpn</i> I	7,8
Equinatoxin II (SEQ ID NO: 37)	36-214 / P17723	31575	pTolE	<i>Bam</i> HI	9,10
NBD1 domain of human CFTR (SEQ ID NO: 38)	460-650 / P13569	33134	pTolT	<i>Bam</i> HI	11,12
Human PDK2 (SEQ ID NO: 39)	18-407 / Q15119	56193	pTolT	<i>Kpn</i> I	13,14
BcrC (SEQ ID NO: 40)	2-203 / P42334	34775	pTolT	<i>Bam</i> HI	15,16
TM1 domain of human CFTR (SEQ ID NO: 41)	2-355 / P13569	52590	pTolT	<i>Bam</i> HI	17,18

^a Mr of fusion protein calculated from the sequence. ^b Restriction site used for cloning at the N-terminal part of the fusion protein. In all cases C-terminal site used was *Mlu*I. ^c

RefSeq accession number. ^d Oligonucleotides to amplify the desired proteins were of the following sequences (all 5'-3'; see Table 1):

1. TTTTGGATCCAATTCCAATGGATGGTCATGGAG (SEQ ID NO: 42)
2. AAGGATCCAAGCTTCAAGGTTTAGGCTTTGAATTATTGTCC (SEQ ID NO: 43)

3. TTTTGGATCCAATGCTTTTGGTGGAGGGAAAAATC (SEQ ID NO: 44)
4. CTCAGCGGTGGCAGCAGCC (SEQ ID NO: 45)
5. CGCGGATCCCATGGGGACAATAATTCAAAGC (SEQ ID NO: 46)
6. GGCGAATTCACGCGTTAAAATAATAATTTCTGGCTCAC (SEQ ID NO: 47)
7. CCGGGGTACCAATTTGGTGAATTTCCACAGAATGATC (SEQ ID NO: 48)
8. GGCGAATTCACGCGTTAGCAACGAGGGGTGCTCCC (SEQ ID NO: 49)
9. CGCGGATCCGCAGACGTGGCTGGCGCC (SEQ ID NO: 50)
10. GGCGAATTCACGCGTTAAGCTTTGCTCACGTGAGTTTC (SEQ ID NO: 51)
11. CGCGGATCCTCTAATGGTGATGACAGCCTC (SEQ ID NO: 52)
12. GGCGAATTCACGCGTTAGAAAGAATCACATCCCATGAG (SEQ ID NO: 53)
13. CCGGGGTACCAAGTACATAGAGCACTTCAGCAAGTTC (SEQ ID NO: 54)
14. GGCGAATTCACGCGTTACGTGACGCGGTACGTGGTCG (SEQ ID NO: 55)
15. CGCGGATCCTTTTCAGAATTAAATATTGATG (SEQ ID NO: 56)
16. GGCGAATTCACGCGTTAAAAGTTCTTCGATTTATCG (SEQ ID NO: 57)
17. CGCGGATCCCAGAGGTCGCCTCTGG (SEQ ID NO: 58)
18. GGCGAATTCACGCGTTAGGGAAATTGCCGAGTGAC (SEQ ID NO: 59)

Expression of proteins in E. coli

All proteins were expressed in an *E. coli* BL21(DE3)pLysE strain (from Novagen). The strain was transformed with plasmid and grown on LB plates with appropriate selection (Ampicillin, Chloramphenicol). One colony was used to inoculate 5 ml of LBAC medium (Ampicillin at 100 µg/ml, Chloramphenicol at 34 µg/ml, both from SIGMA). Bacteria were grown on rotating wheel at 37°C. After 60 min the expression of recombinant proteins was induced by an addition of 1 mM (final) IPTG and bacteria were grown for additional 4 h. Small samples (corresponding to a volume of bacteria which when resuspended in 1 ml yields $A_{600}=0.5$) was analysed on SDS-PAGE. Gels were stained with Coomassie and scanned at 600 dpi using commercial scanner. The amount of expressed proteins was estimated from the gels using the program Tina 2.0. For large-scale expression, 5 ml of bacterial culture in stationary phase was used to inoculate 250 ml of LBAC medium and grown at 37°C in orbital shaker at 180 rpm overnight. The next morning 20-25 ml of overnight culture was used to inoculate 500 ml of M9 LBAC medium. In total 3-5 l of bacterial culture were grown for a single protein. Bacteria were grown at the same

conditions until A_{600} reached approximately 0.8. Then the production of recombinant proteins was induced by adding IPTG to final 1 mM concentration. Bacteria were grown for additional 4-5 h, centrifuged for 5 min at 5000 rpm at 4°C, and stored at -20°C.

Isolation of proteins from bacteria

Pelleted bacteria were resuspended (2 ml of buffer / g of cells) in 50 mM NaH_2PO_4 , pH 8.0, 300 mM NaCl, 10 mM imidazole, 20 mM β -mercaptoethanol (buffer A), with following enzymes and inhibitors of proteases (final concentrations): DNase (10 $\mu\text{g}/\text{ml}$), RNase (20 $\mu\text{g}/\text{ml}$), lysozyme (1 mg/ml of buffer), PMSF (0.5 mM), benzamidine (1mM). They were incubated on ice for an hour and occasionally vigorously shaken. The resuspended bacteria were sonicated for 3 min with a Branson sonicator and then centrifuged in a Beckman ultra-centrifuge at 40000 rpm, 4°C in 45ti rotor. Supernatant was removed and placed at 4°C. Pellet was resuspended in the same buffer without enzymes and inhibitors (1 ml / g of weight) and kept on ice for 15 min. Centrifugation at the same conditions followed after additional 1 min of sonication. Supernatants from both centrifugations were merged and applied at approximately 1 ml/min to 1-3 ml of Ni-NTA resin (Qiagen) equilibrated with buffer A. Typically, column with bound protein was washed with two fractions of 3 ml of buffer A, two fractions of buffer A with 20 mM imidazole and 6-10 fractions of buffer A with 300 mM imidazole. Fractions were analysed on SDS-PAGE. Fractions of interest were pooled and dialysed three times against water (5 l) at 4°C. Purity was checked by SDS-PAGE. Proteins were stored at 4°C in 3 mM NaN_3 . Protein concentration was determined by using extinction coefficients calculated from the sequence.

Fractionation of bacterial proteins

All bacterial proteins were fractionated in order to see the amount of insoluble expressed proteins. Pelleted bacteria from 100 ml of broth were resuspended in 40 ml of 20 % sucrose, 1 mM EDTA, 30 mM Tris-HCl, pH 8.0 and incubated 10 min at room temperature. They were centrifuged at 9000 g for 10 min at 4°C. Supernatant was removed and pellet was gently resuspended in 8 ml of ice-cold 5 mM MgSO_4 . Bacteria were gently shaken and incubated on ice for 10 min. Bacterial protoplasts were centrifuged again at the same conditions. Supernatant was removed as periplasmic fraction. Pellet was resuspended

in 10 ml of 20 mM NaH_2PO_4 , pH 8.0, with 1 mg of lysozyme and benzamidine. It was shaken vigorously and incubated on ice for 30 min, and finally, sonicated 5×30 s. Cytoplasmic proteins were removed from insoluble material by centrifugation at 35 000 g at 4°C for 30 min. Supernatant was removed as cytoplasmic fraction and pellet was resuspended in 2 ml of 8 M urea, 10 mM Tris-HCl, pH 7.4, 0.5 % Triton X-100 as insoluble fraction (membrane proteins and putative inclusion bodies).

Cleavage and purification of TolAIII-R-domain colicin N fusion

Pure R-domain of colicin N was produced using the pTol expression system. 45 mg of TolAIII-R-domain was incubated in 35 ml of cleavage mixture at 20°C for 20 h. Cleavage mixture contains buffer as specified by producer and thrombin (Restriction grade, Novagen) at 0.1 U/mg of fused protein. Cleaved products were dialysed three times against 5 l of 40 mM Tris-HCl, pH8.4 at 4°C, each time at least 4 h. Cleaved R domain was separated from TolAIII and uncleaved fusion protein by ion-exchange chromatography on FPLC system (Pharmacia). Proteins were applied to Mono S column (Pharmacia) at 1 ml/min in 40 mM Tris-HCl, pH8.4. After unbound material was washed from the column, R-domain was eluted by applying gradient of NaCl from 0 to 500 mM in the same buffer in 30 min. Large peak at approximately 70% of NaCl (app. 350 mM) was collected and checked for purity by SDS-PAGE.

Example 2:

Cloning of pTol vector

A DNA fragment encoding BCL-XL was amplified by PCR from the plasmid pETBCLXL using the oligonucleotides SenseBCL-STU (5'- TTT TTT AGG CCT TCT CAG AGC AAC CGG GAG - 3'; SEQ ID NO: 60) and Mlu-BCL-Rev (5' - TTT TAC GCG TTC ATT TCC GAC TGA AGA G - 3'; SEQ ID NO: 61). BCL-XL was introduced into pTOLT plasmid using *Stu* I and *Mlu* I restriction sites. The final plasmid was named as a pTOLT-BCLXL (Figure 7) and DNA sequencing of this plasmid showed that BCL-XL encoding DNA fragment was correctly inserted.

Protein purification

BCL-XL protein was expressed in an *E. coli* BL21 DE3 (pLysE) strain. The strain was transformed with plasmid and grown on LB plates with ampicillin (200 µg/ml) and chloramphenicol (35 µg/ml) selection. 5 ml of LB medium with antibiotics was inoculated with single colony and grown overnight at 37 °C. A 5 ml overnight culture was introduced into 500 ml of LB medium in 2 liter flasks containing ampicillin and chloramphenicol. Bacteria were grown until OD₆₀₀: 0.8 and induced by addition of final concentration 1mM IPTG then grown for additional 3 hours. Cells were harvested and resuspended in 20 mM phosphate, 300mM NaCl, pH: 8.0 buffer containing RNase, DNase, PMSF (1mM) and Benzamidine (1mM). The cells were lysed by French press and the supernatant was obtained by ultra-centrifugation at 40 000 rpm for 1 h. The N-terminal 6X Histidine-tag (SEQ ID NO: 8) facilitated purification of the Tol-BCL fusion by means of Ni-NTA affinity column. The fusion protein was washed onto the column with 20 mM phosphate, 300mM NaCl, pH: 8.0, buffer, additionally washed with the same buffer containing 50 mM imidazole and eluted in 300 mM imidazole, pH 7.0. The expression of fusion protein was analysed by SDS-PAGE (Figure 8) and concentration of protein was determined by UV absorption at 280 nm.

Thrombin cleavage of the BCL-XL protein

20 mg of TolA-BCL fusion was incubated in 20 ml of cleavage buffer at 4 °C for 4 h. Cleavage buffer contains 50mM Tris-HCl, 150mM NaCl, 2.5 mM CaCl₂, 5 mM DTT and Thrombin (1Unit of thrombin (Sigma)/mg of fused protein). The released protein was recovered applying overnight dialysed cleavage mixture to a Ni-NTA column. After unbound protein was washed from the column, remains of the BCL-XL protein was washed by 2 M NaCl. All flow through and washes were collected and analysed by SDS-PAGE (Figure 9). The protein yields were calculated after thrombin cleavage using UV absorbance at 280 nm.

RESULTS

Expression of TolAIII protein in E. coli

In Example 1, the third domain of TolAIII with tags (Figure 2) was expressed from three different expression vectors (Figure 3), pTolE, pTolT, and pTolX. In each case, the

expression of TolAIII was huge, sometimes reaching up to 40 % of all bacterial proteins (see Figure 3A). Specifically, the amount of expressed TolAIII from pTolT was $26.96 \% \pm 1.67$ (n=5). The amount of expressed TolAIII was approximately the same regardless which vector was used. TolA expressed in bacteria did not interfere with normal bacterial metabolism. The growth curve was very similar for induced and non-induced bacteria (Figure 3B). All of the TolAIII protein was expressed in soluble form. No inclusion bodies were revealed by visual inspection of pelleted remains of bacteria after osmotic lysis, lysozyme treatment, sonication, and centrifugation. Furthermore, none of the TolAIII was found in insoluble cell fraction after fractionation of proteins from bacteria. Insoluble fraction represents membrane proteins and should contain also recombinant proteins in inclusion bodies (Figure 3C). Bacteria containing TolAIII were a bit more fragile than normal. TolAIII was released from the cells already after mild hypo-osmotic treatment, which should release only periplasmic proteins.

Expression of other proteins in E. coli as fusions with TolAIII

Ten proteins were tested in order to check the suitability of pTol expression system for expression and preparation of other proteins (see Example 1, Table 1, and Example 2). These were different parts and domains of colicin N (TolA binding box (peptide of amino acids 40-76), deletion mutant of T-domain ($\Delta 10$) and R domain), representing prokaryotic proteins. Human phospholipase A₂, pore-forming protein from sea anemone equinatoxin II, nucleotide binding domain 1 (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR), human mitochondrial pyruvate dehydrogenase kinase 2 (PDK2) and BCL-XL were examples of eukaryotic proteins. Transmembrane proteins were represented by BcrC, a component of bacitracin resistance system from *B. licheniformis*, and transmembrane domain 1 (TM1) of human CFTR. Proteins chosen represent variations in size (app. 4.4 of colicin 40-76 kDa vs. 44 kDa of PDK2), genetic code (prokaryotic vs. eukaryotic proteins), protein location (soluble vs. membrane), and disulphide content (PLA₂, 7 disulphides vs. equinatoxin, none). Fusion proteins were expressed at high proportion in *E. coli* using pTol system (Figure 4). Again, the expression was as high as 40% in some cases, but the average was around 20-25 % (see Figure 4B and C bottom panels). The only two exceptions were membrane proteins, BcrC and TM1. In this case a band corresponding to their size was lacking from the gel (Figure 4C). As opposed to

expression of TolAIII alone, expression of fusion proteins interferes with the growth of bacteria. In the case of PLA₂ and membrane proteins, TM1 and BcrC, the amount of bacteria at the end of the growth halved in some cases. Interestingly, expression of fusion of PDK2 in bacterial cell had positive effect and there was always slightly more bacteria at the end of the growth (not shown). Some of the bacteria expressing fusions were further fractionated. PDK2 and PLA2 were expressed as insoluble inclusion bodies. EqtII and R-domain were found mainly in the insoluble fraction, but some proportion was found also in cytoplasmic fraction (10-25 % of expressed proteins) (not shown).

Isolation and cleavage of fusion proteins

In Example 1, expressed fusions were isolated from the cytoplasm by simple extraction into buffered solution, which was applied onto Ni-NTA column. By this single step proteins were already more than 95 % pure (Figure 5). Yields of isolated fusions were on average approximately 50 mg/l of bacterial broth, but reached up to 90 mg/l (Table 2). Even proteins, which were mainly expressed as inclusion bodies, were isolated in significant quantities by this procedure, i.e. 11 mg/ml of EqtII fusion was isolated. One of the fusion proteins, TolE-Tdomain 40-76, was used for the preparation of a peptide sample suitable for structure determination by NMR. It was expressed in M9 minimal media containing ¹⁵NH₄Cl. Even in minimal media it was possible to express and produce fusion at significant amounts, almost 70 mg of pure fusion was obtained per litre of bacterial culture.

Table 2: Yields of isolated fusion proteins by using pTol system

Protein ^a	Yield (mg/l bacterial broth)
TolE-Tdomain 40-76	46.7
¹⁵ N TolE-Tdomain 40-76	67.1
TolT-Tdomain 40-76	83.8
TolX-Tdomain 40-76	89.6
TolT-Δ10 Tdomain	37.4
TolT-Rdomain	51

TolE- EqtII	11
TolT-PDK	1.4

^a Proteins are named after plasmid used for expression of fusion protein.

Pure R-domain was prepared from TolT-Rdomain fusion by cleavage with thrombin and separation of cleavage products by ion-exchange chromatography. The results of such purification scheme are presented on Figure 5. By the outlined procedure 13 mg of pure functional R domain was prepared from 1 l of starting bacterial culture. Slightly lower yield as expected from the amount of soluble fusion is a consequence of R-domain precipitation during the preparation. However, yield presented here is still more than two times higher than the system which provides directly expressed R-domain.

We show in Example 2 that BCL-XL, an important protein in apoptosis and cancer research, can be expressed in large quantities as a fusion with TolAIII (see Figure 8). SDS-PAGE analysis of the TolA-BCL fusion protein revealed a band with an apparent molecular weight of about 35 kD, which is in agreement with the following theoretical calculations:

ProtParamaters of TolA-BCL fusion protein (SEQ ID NO: 14):

Number of amino acids: 348

Molecular weight: 38048.5

Theoretical pI: 5.83

Amino acid composition:

Ala (A)	38	10.9%
Arg (R)	17	4.9%
Asn (N)	17	4.9%
Asp (D)	16	4.6%

Cys (C)	3	0.9%
Gln (Q)	13	3.7%
Glu (E)	24	6.9%
Gly (G)	29	8.3%
His (H)	10	2.9%
Ile (I)	12	3.4%
Leu (L)	28	8.0%
Lys (K)	16	4.6%
Met (M)	7	2.0%
Phe (F)	16	4.6%
Pro (P)	17	4.9%
Ser (S)	34	9.8%
Thr (T)	13	3.7%
Trp (W)	7	2.0%
Tyr (Y)	10	2.9%
Val (V)	21	6.0%
Asx (B)	0	0.0%
Glx (Z)	0	0.0%
Xaa (X)	0	0.0%

Total number of negatively charged residues (Asp + Glu): 40

Total number of positively charged residues (Arg + Lys): 33

Extinction coefficients:

Conditions: 6.0 M guanidium hydrochloride, 0.02 M phosphate buffer, pH 6.5

Extinction coefficients are in units of $M^{-1} \text{ cm}^{-1}$.

The first table lists values computed assuming ALL Cys residues appear as half cystines, whereas the second table assumes that NONE do.

276	278	279	280	282
nm	nm	nm	nm	nm

Ext. coefficient	52445	53327	53190	52750	51320
Abs 0.1% (=1 g/l)	1.378	1.402	1.398	1.386	1.349
	276	278	279	280	282
	nm	nm	nm	nm	nm
Ext. coefficient	52300	53200	53070	52630	51200
Abs 0.1% (=1 g/l)	1.375	1.398	1.395	1.383	1.346

The TolAIII domain was cleaved from the TolA-BCL fusion using thrombin and the BCL partner purified on a Ni-NTA column (Figure 9). We found that 1 litre of BL21 (DE3) pLys E *E. Coli* cell culture gave 20 mg of highly pure, thrombin-cleaved BCL-XL protein. The SDS-PAGE apparent molecular weight following thrombin cleavage (see Figure 9) was in agreement with the following theoretical calculations:

ProtParamaters of the cleaved BCLXL component TolA-BCL fusion after thrombin treatment (SEQ ID NO: 15):

Number of amino acids: 236

Molecular weight: 26329.2

Theoretical pI: 4.94

Amino acid composition:

Ala (A)	22	9.3%
Arg (R)	15	6.4%
Asn (N)	12	5.1%
Asp (D)	10	4.2%
Cys (C)	1	0.4%
Gln (Q)	10	4.2%
Glu (E)	21	8.9%
Gly (G)	18	7.6%
His (H)	4	1.7%

Ile (I)	6	2.5%
Leu (L)	19	8.1%
Lys (K)	6	2.5%
Met (M)	5	2.1%
Phe (F)	13	5.5%
Pro (P)	8	3.4%
Ser (S)	24	10.2%
Thr (T)	11	4.7%
Trp (W)	7	3.0%
Tyr (Y)	6	2.5%
Val (V)	18	7.6%
Asx (B)	0	0.0%
Glx (Z)	0	0.0%
Xaa (X)	0	0.0%

Total number of negatively charged residues (Asp + Glu): 31

Total number of positively charged residues (Arg + Lys): 21

Extinction coefficients:

Conditions: 6.0 M guanidium hydrochloride 0.02 M phosphate buffer pH 6.5

Extinction coefficients are in units of $M^{-1} \text{ cm}^{-1}$.

The first table lists values computed assuming ALL Cys residues appear as half cystines, whereas the second table assumes that NONE do.

	276	278	279	280	282
	nm	nm	nm	nm	nm
Ext. coefficient	46500	47600	47690	47510	46400
Abs 0.1% (=1 g/l)	1.766	1.808	1.811	1.804	1.762

	276	278	279	280	282
	nm	nm	nm	nm	nm

Ext. coefficient	46500	47600	47690	47510	46400
Abs 0.1% (=1 g/l)	1.766	1.808	1.811	1.804	1.762

DISCUSSION

TolAIII is expressed in huge quantities in soluble form in bacterial cytoplasm. Among the reasons for high expression of proteins in *E. coli* are most commonly cited appropriate codon usage, stability of mRNA transcript, size, content of disulphide bonds, and non-toxicity to the cell. TolAIII is small protein, with only one disulphide bond. It is very stable and monomeric in solution even at concentrations as high as 30 mg/ml (data from analytical ultracentrifugation and gel filtration, not shown). The small size and tendency not to aggregate are certainly important in tolerance of heterologous material in the cytoplasm of bacteria. A further advantage of TolAIII gene is, that it is bacterial protein and as such it possesses only 5 codons (4.7 % of 106 amino acids excluding protease cleavage site) rarely transcribed in *E. coli* genome. They are scattered along the sequence. An improvement of its expression could be achieved by engineering of the conformation of its mRNA transcript. It was shown that, for a high yield of transcribed RNA, sometimes the conformation of RNA should be such, that the ribosome binding site and start codon should be exposed and not involved in base pairing. In the case of TolAIII mRNA both are involved in building short stems and not always completely exposed (analysis of transcribed RNAs of 60-120 nucleotides (step of 10 nt) by Mfold on <http://bioinfo.math.rpi.edu/~zukerm/>). High expression of TolAIII protein in the T7 based vector and the high yields of pure product are comparable or even better than published and existing systems for production of fusion proteins in *E. coli*.

We have employed a domain of a periplasmic bacterial protein as a fusion partner in the overexpression of various proteins of bacterial and eukaryotic origin. Some small peptides or domains could be attached to TolAIII without significantly changing its size. The same amount of expressed protein would then be expected. In fact, the yield of fusion containing colicin N 40-76 peptide was the same as for TolAIII itself. The system is suitable for the preparation of eukaryotic proteins as well. In particular, the level of expression of EqtII is much more improved over the published one. Approximately 20 % of total expression of the fusion contrasted with approximately 5 % in the case of direct expression. The

majority of EqtII expressed from the pTol system is in the insoluble fraction, but isolation of the soluble cytoplasmic fraction still resulted in a large improvement in yield over the published method. The pTol system might also be applicable for proteins expressed as inclusion bodies. For example, the amount of expressed PLA₂ is similar to other expression systems, however the fusion protein can easily be isolated by Ni-NTA chromatography and then refolded and cleaved on the column matrix. An interesting observation was that the two membrane proteins studied did not express as fusion proteins with pTolA system, although the reason for this is unclear at the moment.

Three expression vectors were constructed providing three different cleavage sites for endopeptidases widely used in molecular biology, e.g. enterokinase, factor Xa and thrombin. Recognition sites for endopeptidases differ in amino acid sequence and size. These differences dramatically change properties of the small TolAIII partner in fusion proteins (Table 3). TolAT and TolAX are basic, calculated pI more than 8.5, TolAE is acid in nature, pI of 6.6. This is the result of four aspartates in the recognition sequence for enterokinase (DDDDK; SEQ ID NO: 3). The constructed vectors thus enable higher flexibility, *i.e.* one can easily choose appropriate vector on the basis of the properties of fused partner. In our case, R-domain of colicin N was expressed in pTolT vector since R-domain is even more basic (pI 9.7) than cleaved TolAIII. On the other hand, colicin N peptide 40-76 has almost the same pI as TolAT or TolAX. This make subsequent purification much more difficult, the peaks representing the peptide and TolAIII would then overlap in ion-exchange chromatography. Therefore, peptide was expressed in pTolE. Cleaved TolAIII was not bound to the column at chosen conditions and the difference in pI of the uncleaved fusion (pI 7.2) and peptide was large enough to get clearly resolved peaks (not shown).

Table 3: Physical properties of TolAIII proteins after endoprotease cleavage

Protein ^a	Amino acids	Mw ^b	pI ^b
TolAE	111	11716.1	6.57
TolAT	110	11593.2	8.93
TolAX	110	11583.1	8.57

^a Proteins are named according to the vector in which they were produced. ^b Calculated from the sequence.

We could produce functional parts of the colicin N toxin by using the pTol expression system. We produced functional R-domain and 39 residue peptide composed of colicin residues 40-76. His-tagged R-domain expresses poorly and irreproducibly and the tolA fusion expressed consistently well and improved the yield by more than two fold. Peptide was produced as ¹⁵N labelled sample for NMR structure determination. Preparation of large quantities of labelled peptide sample for NMR structure analysis can be problematic and a significant financial burden to research groups. High yields and versatility of the pTol system should make preparation of short peptides and proteins much cheaper and alternative to chemical synthesis and other expression systems. The system may be particularly useful for reproducible high level expression of small (<20 kDa) soluble proteins and unstructured peptides. For example, the system might prove useful in the preparation of ¹⁵N or ¹³C labelled small peptides for NMR structural studies.

The expression of BCL-XL, an important protein in apoptosis and cancer research, is difficult to express at high yield since it has a hydrophobic C-terminal region which causes instability and toxicity. Thus most structural work has been carried out on truncated versions lacking this region. We were unable to express this protein in satisfactory yields for structural studies and thus used the TolAIII fusion protein system to improve our yields. We can now express large amounts of this protein as a TolAIII fusion partner (Figure 8). It is well folded as judged by CD spectroscopy (not shown). We can also produce large amounts in minimal media including ¹⁵NH₄Cl as the only nitrogen source.

CLAIMS

1. A fusion polypeptide for expression in a host cell comprising a TolAIII domain or a functional homologue, fragment, or derivative thereof and a non-TolA polypeptide, wherein the TolAIII domain or functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and the non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide.
2. The fusion polypeptide according to claim 1, further comprising a signal peptide.
3. The fusion polypeptide according to claim 2, in which the signal peptide is located at or near the N-terminus of the fusion polypeptide.
4. The fusion polypeptide according to any preceding claim, wherein the TolAIII domain or functional homologue, fragment, or derivative thereof has been codon-optimised for expression in the host cell.
5. The fusion polypeptide according to any of the preceding claims, further comprising a linker between the TolAIII domain or functional homologue, fragment, or derivative thereof and the non-TolA polypeptide.
6. The fusion polypeptide according to claim 5, wherein the linker comprises at least one cleavage site for an endopeptidase.
7. The fusion polypeptide according to claim 6, wherein the cleavage site comprises the amino acid sequence DDDDK (SEQ ID NO: 3) and/or LVPR (SEQ ID NO: 4) and/or IEGR (SEQ ID NO: 5).
8. The fusion polypeptide according to any of the preceding claims, further comprising an affinity purification tag.
9. The fusion polypeptide according to claim 8, wherein the affinity purification tag is

located at or near the N-terminus of the fusion polypeptide.

10. The fusion polypeptide according to claim 9, wherein the affinity purification tag is an N-terminal His_n tag, with n=4, 5, 6, 7, 8, 9 or 10 (SEQ ID NOs: 6 – 12, respectively; preferably n=6 [SEQ ID NO: 8]), optionally with the His_n tag linked to the fusion polypeptide by one or more Ser residues (preferably 2).

11. The fusion polypeptide according to any of the preceding claims, wherein the TolAIII domain consists of amino acid residues 329-421 (SEQ ID NO: 13) of the *Escherichia coli* TolA sequence (SwissProt Acc. No. P19934).

12. The fusion polypeptide according to any of the preceding claims, wherein the host cell is bacterial (for example, *Escherichia coli*).

13. The fusion polypeptide according to any of the preceding claims, wherein the non-TolA polypeptide is BCL-XL.

14. A DNA molecule encoding the fusion polypeptide as defined in any of claims 1-13.

15. A DNA molecule according to claim 14, wherein the mRNA properties of the DNA molecule when transcribed are optimised for expression in the host cell.

16. An expression vector comprising the DNA molecule according to either of claim 14 or claim 15 for expression of the fusion polypeptide defined in any of claims 1-13.

17. The expression vector according to claim 16, having an inducible promoter (for example, the IPTG-inducible T7 promoter) which drives expression of the fusion polypeptide.

18. The expression vector according to either of claim 16 or claim 17, having an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).

19. A cloning vector for producing the expression vector defined in any of claims 16-18, comprising DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof upstream or downstream from a cloning site which allows in-frame insertion of DNA encoding a non-TolA polypeptide.
20. The cloning vector according to claim 19, further comprising DNA encoding at least one cleavage site (for example, the amino acid sequence DDDDK [SEQ ID NO: 3] and/or LVPR [SEQ ID NO: 4] and/or IEGR [SEQ ID NO: 5]) for an endopeptidase, the cleavage site located between the DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof and the cloning site.
21. The cloning vector according to either of claims 19 or 20, wherein the cloning site comprises at least one restriction endonuclease (for example, *Bam*HI and/or *Kpn*I) target sequence.
22. The cloning vector according to any of claims 19-21, further comprising DNA encoding an affinity purification tag as defined in either of claim 8 or claim 9.
23. The cloning vector according to any of claims 19-22, further comprising an inducible promoter (for example, the IPTG-inducible T7 promoter).
24. The cloning vector according to any of claims 19-23, further comprising DNA encoding an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).
25. The cloning vector according to any of claims 19-24, having the structure of pTolE, pTolT or pTolX (as shown in Figure 2 with reference to the description).
26. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of a fusion polypeptide as defined in any of claims 1-13.

27. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of the DNA molecule as defined in either of claim 14 or claim 15.
28. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of an expression vector as defined in any of claims 16-18.
29. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of a cloning vector as defined in any of claims 19-25.
30. A host cell containing the DNA as defined in claim 13 and/or the expression vector as defined in any of claims 16-18 and/or the cloning vector as defined in any of claims 19-25.
31. Use of the fusion polypeptide as defined in any of claims 5-13 for immobilisation of the non-TolA polypeptide, comprising the step of:
binding the fusion polypeptide to a TolA binding polypeptide (e.g. the TolA-recognition site of colicin N or other colicins, the TolA binding region of bacteriophage g3p-D1 protein, or the TolA binding region of TolB or other Tol proteins).
32. Use of the fusion polypeptide as defined in any of claims 9-13 for immobilisation of the non-TolA polypeptide, comprising the step of:
binding the affinity tag of the fusion polypeptide to a binding moiety.
33. Use of the fusion polypeptide as defined in any of claims 5-13 for purification and isolation of the non-TolA polypeptide, comprising the steps of:
(i) binding the fusion polypeptide to a TolA binding polypeptide (e.g. the TolA-recognition site of colicin N or other colicins, the TolA binding region of bacteriophage g3p-D1 protein, or the TolA binding region of TolB or other Tol proteins);
(ii) cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and
(iii) separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

34. Use of the fusion polypeptide as defined in any of claims 8-13 for purification and isolation of the non-TolA polypeptide, comprising the steps of:

- (i) binding the affinity tag of the fusion polypeptide to a binding moiety;
- (ii) cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and
- (iii) separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

35. Use of the fusion polypeptide as defined in any of claims 1-13 for studying interaction properties of the non-TolA polypeptide or the fusion polypeptide, for example self-interaction, interaction with another molecule, or interaction with a physical stimulus.

36. A method for high expression of a polypeptide as a fusion polypeptide in a host cell, comprising the step of expressing the polypeptide as a fusion polypeptide as defined in any of claims 1-13 in a host cell.




Fig. 1 (Prior Art)







Fig. 2

3/9

Fig. 3

4/9

Fig. 3 (cont.)

5/9







Fig. 4

6/9



Fig. 5

Fig. 6

8/9

Fig. 7

9/9

Fig. 8Fig. 9

SEQUENCE LISTING

<110> University of Newcastle Upon Tyne

<120> Fusion Proteins

<130> 43952/JMD/MAR

<150> GB 0200689.8

<151> 2002-01-10

<160> 61

<170> PatentIn version 3.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Ala3-His6 tail

<400> 1

Ala Ala Ala His His His His His His

1 5

<210> 2

<211> 25

<212> PRT

<213> Escherichia coli

<400> 2

Met Asn Met Lys Lys Leu Ala Thr Leu Val Ser Ala Val Ala Leu Ser

1 5 10 15

Ala Thr Val Ser Ala Asn Ala Met Ala

20 25

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Cleavage site for enterokinase

<400> 3

Asp Asp Asp Asp Lys

1

5

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Cleavage site for thrombin

<400> 4

Leu Val Pro Arg

1

<210> 5

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Cleavage site for factor Xa

<400> 5

Ile Glu Gly Arg

1

<210> 6

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> 4xHis tag

<400> 6

His His His His

1

<210> 7

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> 5xHis tag

<400> 7

His His His His His

1 5

<210> 8

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> 6xHis tag

<400> 8

His His His His His His

1 5

<210> 9

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> 7xHis tag

<400> 9

His His His His His His His

1 5

<210> 10

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> 8xHis tag

<400> 10

His His His His His His His His

1 5

<210> 11

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> 9xHis tag

<400> 11

His His His His His His His His

1 5

<210> 12

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> 10xHis tag

<400> 12

His His His His His His His His His

1 5 10

<210> 13

<211> 93

<212> PRT

<213> Escherichia coli

<400> 13

Asn Asn Gly Ala Ser Gly Ala Asp Ile Asn Asn Tyr Ala Gly Gln Ile

1 5 10 15

Lys Ser Ala Ile Glu Ser Lys Phe Tyr Asp Ala Ser Ser Tyr Ala Gly

20 25 30

Lys Thr Cys Thr Leu Arg Ile Lys Leu Ala Pro Asp Gly Met Leu Leu

35 40 45

Asp Ile Lys Pro Glu Gly Gly Asp Pro Ala Leu Cys Gln Ala Ala Leu

50 55 60

Ala Ala Ala Lys Leu Ala Lys Ile Pro Lys Pro Pro Ser Gln Ala Val

65 70 75 80

Tyr Glu Val Phe Lys Asn Ala Pro Leu Asp Phe Lys Pro

85 90

<210> 14

<211> 348

<212> PRT

<213> Artificial Sequence

<220>

<223> TolA-BCL fusion protein

<400> 14

Met His His His His His His Ser Ser Asn Asn Gly Ala Ser Gly Ala
1 5 10 15

Asp Ile Asn Asn Tyr Ala Gly Gln Ile Lys Ser Ala Ile Glu Ser Lys
20 25 30

Phe Tyr Asp Ala Ser Ser Tyr Ala Gly Lys Thr Cys Thr Leu Arg Ile
35 40 45

Lys Leu Ala Pro Asp Gly Met Leu Leu Asp Ile Lys Pro Glu Gly Gly
50 55 60

Asp Pro Ala Leu Cys Gln Ala Ala Leu Ala Ala Lys Leu Ala Lys
65 70 75 80

Ile Pro Lys Pro Pro Ser Gln Ala Val Tyr Glu Val Phe Lys Asn Ala
85 90 95

Pro Leu Asp Phe Lys Pro Gly Gly Gly Ser Gly Ser Leu Val Pro Arg
100 105 110

Gly Ser Arg Pro Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu
115 120 125

Ser Tyr Lys Leu Ser Gln Lys Gly Tyr Ser Trp Ser Gln Phe Ser Asp
130 135 140

Val Glu Glu Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Glu Met
145 150 155 160

Glu Thr Pro Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp
165 170 175

Ser Pro Ala Val Asn Gly Ala Thr Ala His Ser Ser Ser Leu Asp Ala
180 185 190

Arg Glu Val Ile Pro Met Ala Ala Val Lys Gln Ala Leu Arg Glu Ala
195 200 205

Gly Asp Glu Phe Glu Leu Arg Tyr Arg Arg Ala Phe Ser Asp Leu Thr
 210 215 220

Ser Gln Leu His Ile Thr Pro Gly Thr Ala Tyr Gln Ser Phe Glu Gln
 225 230 235 240

Val Val Asn Glu Leu Phe Arg Asp Gly Val Asn Trp Gly Arg Ile Val
 245 250 255

Ala Phe Phe Ser Phe Gly Gly Ala Leu Cys Val Glu Ser Val Asp Lys
 260 265 270

Glu Met Gln Val Leu Val Ser Arg Ile Ala Ala Trp Met Ala Thr Tyr
 275 280 285

Leu Asn Asp His Leu Glu Pro Trp Ile Gln Glu Asn Gly Gly Trp Asp
 290 295 300

Thr Phe Val Glu Leu Tyr Gly Asn Asn Ala Ala Ala Glu Ser Arg Lys
 305 310 315 320

Gly Gln Glu Arg Phe Asn Arg Trp Phe Leu Thr Gly Met Thr Val Ala
 325 330 335

Gly Val Val Leu Leu Gly Ser Leu Phe Ser Arg Lys
 340 345

<210> 15

<211> 236

<212> PRT

<213> Artificial Sequence

<220>

<223> Tola-BCL fusion protein after thrombin cleavage

<400> 15

Gly Ser Arg Pro Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu
 1 5 10 15

Ser Tyr Lys Leu Ser Gln Lys Gly Tyr Ser Trp Ser Gln Phe Ser Asp
 20 25 30

Val Glu Glu Asn Arg Thr Glu Ala Pro Glu Gly Thr Glu Ser Glu Met
 35 40 45

Glu Thr Pro Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp
 50 55 60

Ser Pro Ala Val Asn Gly Ala Thr Ala His Ser Ser Ser Leu Asp Ala
 65 70 75 80

Arg Glu Val Ile Pro Met Ala Ala Val Lys Gln Ala Leu Arg Glu Ala
 85 90 95

Gly Asp Glu Phe Glu Leu Arg Tyr Arg Arg Ala Phe Ser Asp Leu Thr
 100 105 110

Ser Gln Leu His Ile Thr Pro Gly Thr Ala Tyr Gln Ser Phe Glu Gln
 115 120 125

Val Val Asn Glu Leu Phe Arg Asp Gly Val Asn Trp Gly Arg Ile Val
 130 135 140

Ala Phe Phe Ser Phe Gly Gly Ala Leu Cys Val Glu Ser Val Asp Lys
 145 150 155 160

Glu Met Gln Val Leu Val Ser Arg Ile Ala Ala Trp Met Ala Thr Tyr
 165 170 175

Leu Asn Asp His Leu Glu Pro Trp Ile Gln Glu Asn Gly Gly Trp Asp
 180 185 190

Thr Phe Val Glu Leu Tyr Gly Asn Asn Ala Ala Ala Glu Ser Arg Lys
 195 200 205

Gly Gln Glu Arg Phe Asn Arg Trp Phe Leu Thr Gly Met Thr Val Ala
 210 215 220

Gly Val Val Leu Leu Gly Ser Leu Phe Ser Arg Lys
 225 230 235

<210> 16

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> Tagged TolAIII region of pTol vectors

<220>

<221> MISC_FEATURE

<222> (107)..(111)

<223> Xaa residues represent cleavage sites DDDDK (SEQ ID NO: 3), LVPR
(SEQ ID NO: 4; no Xaa at position 111) or IEGR (SEQ ID NO: 5; no
Xaa at position 111)

<400> 16

Met His His His His His His Ser Ser Asn Asn Gly Ala Ser Gly Ala
1 5 10 15

Asp Ile Asn Asn Tyr Ala Gly Gln Ile Lys Ser Ala Ile Glu Ser Lys
20 25 30

Phe Tyr Asp Ala Ser Ser Tyr Ala Gly Lys Thr Cys Thr Leu Arg Ile
35 40 45

Lys Leu Ala Pro Asp Gly Met Leu Leu Asp Ile Lys Pro Glu Gly Gly
50 55 60

Asp Pro Ala Leu Cys Gln Ala Ala Leu Ala Ala Ala Lys Leu Ala Lys
65 70 75 80

Ile Pro Lys Pro Pro Ser Gln Ala Val Tyr Glu Val Phe Lys Asn Ala
85 90 95

Pro Leu Asp Phe Lys Pro Gly Gly Gly Ser Xaa Xaa Xaa Xaa Xaa Gly
100 105 110

Ser Gly Thr
115

<210> 17

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> His6-Ser2 linker

<400> 17

His His His His His His Ser Ser
1 5

<210> 18

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Short flexible polypeptide

<400> 18

Gly Gly Gly Ser

1

<210> 19

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Cleavage/cloning site of pTolE vector

<400> 19

ggtgggggat ctgatgatga cgataaagga tccggtacct gatgaacgcg t

51

<210> 20

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Cleavage/cloning site of pTolT vector

<400> 20

ggtgggggat ctctggttcc gcgcggatcc ggtacctgat gaacgcgt

48

<210> 21

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Cleavage/cloning site of pTolX vector

<400> 21

ggtgggggat ctattgaagg tcgcggatcc ggtacctgat gaacgcgt

48

<210> 22

<211> 17

<212> PRT
<213> Artificial Sequence

<220>
<223> Cleavage/cloning site of pTolE vector
<220>
<221> MISC_FEATURE
<222> (14)..(15)
<223> Xaa represents stop codon site

<400> 22
Gly Gly Gly Ser Asp Asp Asp Asp Lys Gly Ser Gly Thr Xaa Xaa Thr
1 5 10 15

Arg

<210> 23
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Cleavage/cloning site of pTolT vector
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> Xaa represents stop codon site

<400> 23
Gly Gly Gly Ser Leu Val Pro Arg Gly Ser Gly Thr Xaa Xaa Thr Arg
1 5 10 15

<210> 24
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Cleavage/cloning site of pTolX vector
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> Xaa represents stop codon site

<400> 24

Gly Gly Gly Ser Ile Glu Gly Arg Gly Ser Gly Thr Xaa Xaa Thr Arg

1

5

10

15

<210> 25

<211> 2

<212> PRT

<213> Artificial Sequence

<220>

<223> Gly-Ser tag

<400> 25

Gly Ser

1

<210> 26

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Gly-Ser-Gly-Thr tag

<400> 26

Gly Ser Gly Thr

1

<210> 27

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 27

gatctgatga tgacgataaa ggatccggta cctgatgaa

39

<210> 28

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 28

cgcggttcac aggtaccgga tcctttatcg tcatcatca

39

<210> 29

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 29

gatctattga aggtcgcgga tccggtacct gatgaa

36

<210> 30

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 30

cgcggttcac aggtaccgga tccggtacct tcaata

36

<210> 31

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 31

gatctctggt tccggtcgga tccggtacct gatgaa

36

<210> 32

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 32

cgcggttcac aggtaccgga tccggtcgga accaga

36

<210> 33

<211> 37

<212> PRT

<213> Escherichia coli

<400> 33

Asn Ser Asn Gly Trp Ser Trp Ser Asn Lys Pro His Lys Asn Asp Gly
 1 5 10 15

Phe His Ser Asp Gly Ser Tyr His Ile Thr Phe His Gly Asp Asn Asn
 20 25 30

Ser Lys Pro Lys Pro
 35

<210> 34

<211> 80

<212> PRT

<213> Escherichia coli

<400> 34

Asn Asn Ala Phe Gly Gly Gly Lys Asn Pro Gly Ile Gly Asn Thr Ser
 1 5 10 15

Gly Ala Gly Ser Asn Gly Ser Ala Ser Ser Asn Arg Gly Asn Ser Asn
 20 25 30

Gly Trp Ser Trp Ser Asn Lys Pro His Lys Asn Asp Gly Phe His Ser
 35 40 45

Asp Gly Ser Tyr His Ile Thr Phe His Gly Asp Asn Asn Ser Lys Pro
 50 55 60

Lys Pro Gly Gly Asn Ser Gly Asn Arg Gly Asn Asn Gly Asp Gly Ala
 65 70 75 80

<210> 35

<211> 117

<212> PRT

<213> Escherichia coli

<400> 35

His Gly Asp Asn Asn Ser Lys Pro Lys Pro Gly Gly Asn Ser Gly Asn
 1 5 10 15

Arg Gly Asn Asn Gly Asp Gly Ala Ser Ala Lys Val Gly Glu Ile Thr
 20 25 30

Ile Thr Pro Asp Asn Ser Lys Pro Gly Arg Tyr Ile Ser Ser Asn Pro
 35 40 45

Glu Tyr Ser Leu Leu Ala Lys Leu Ile Asp Ala Glu Ser Ile Lys Gly
 50 55 60

Thr Glu Val Tyr Thr Phe His Thr Arg Lys Gly Gln Tyr Val Lys Val
 65 70 75 80

Thr Val Pro Asp Ser Asn Ile Asp Lys Met Arg Val Asp Tyr Val Asn
 85 90 95

Trp Lys Gly Pro Lys Tyr Asn Asn Lys Leu Val Lys Arg Phe Val Ser
 100 105 110

Gln Phe Leu Leu Phe
 115

<210> 36
 <211> 124
 <212> PRT
 <213> Homo sapiens

<400> 36
 Asn Leu Val Asn Phe His Arg Met Ile Lys Leu Thr Thr Gly Lys Glu
 1 5 10 15

Ala Ala Leu Ser Tyr Gly Phe Tyr Gly Cys His Cys Gly Val Gly Gly
 20 25 30

Arg Gly Ser Pro Lys Asp Ala Thr Asp Arg Cys Cys Val Thr His Asp
 35 40 45

Cys Cys Tyr Lys Arg Leu Glu Lys Arg Gly Cys Gly Thr Lys Phe Leu
 50 55 60

Ser Tyr Lys Phe Ser Asn Ser Gly Ser Arg Ile Thr Cys Ala Lys Gln
 65 70 75 80

Asp Ser Cys Arg Ser Gln Leu Cys Glu Cys Asp Lys Ala Ala Ala Thr
 85 90 95

Cys Phe Ala Arg Asn Lys Thr Thr Tyr Asn Lys Lys Tyr Gln Tyr Tyr
 100 105 110

Ser Asn Lys His Cys Arg Gly Ser Thr Pro Arg Cys
 115 120

<210> 37

<211> 179

<212> PRT

<213> Actinia equina

<400> 37

Ser Ala Asp Val Ala Gly Ala Val Ile Asp Gly Ala Ser Leu Ser Phe
 1 5 10 15

Asp Ile Leu Lys Thr Val Leu Glu Ala Leu Gly Asn Val Lys Arg Lys
 20 25 30

Ile Ala Val Gly Val Asp Asn Glu Ser Gly Lys Thr Trp Thr Ala Leu
 35 40 45

Asn Thr Tyr Phe Arg Ser Gly Thr Ser Asp Ile Val Leu Pro His Lys
 50 55 60

Val Pro His Gly Lys Ala Leu Leu Tyr Asn Gly Gln Lys Asp Arg Gly
 65 70 75 80

Pro Val Ala Thr Gly Ala Val Gly Val Leu Ala Tyr Leu Met Ser Asp
 85 90 95

Gly Asn Thr Leu Ala Val Leu Phe Ser Val Pro Tyr Asp Tyr Asn Trp
 100 105 110

Tyr Ser Asn Trp Trp Asn Val Arg Ile Tyr Lys Gly Lys Arg Arg Ala
 115 120 125

Asp Gln Arg Met Tyr Glu Glu Leu Tyr Tyr Asn Leu Ser Pro Phe Arg
 130 135 140

Gly Asp Asn Gly Trp His Thr Arg Asn Leu Gly Tyr Gly Leu Lys Ser
 145 150 155 160

Arg Gly Phe Met Asn Ser Ser Gly His Ala Ile Leu Glu Ile His Val

165

170

175

Ser Lys Ala

<210> 38

<211> 191

<212> PRT

<213> Homo sapiens

<400> 38

Thr Gly Ala Gly Lys Thr Ser Leu Leu Met Met Ile Met Gly Glu Leu
 1 5 10 15

Glu Pro Ser Glu Gly Lys Ile Lys His Ser Gly Arg Ile Ser Phe Cys
 20 25 30

Ser Gln Phe Ser Trp Ile Met Pro Gly Thr Ile Lys Glu Asn Ile Ile
 35 40 45

Phe Gly Val Ser Tyr Asp Glu Tyr Arg Tyr Arg Ser Val Ile Lys Ala
 50 55 60

Cys Gln Leu Glu Glu Asp Ile Ser Lys Phe Ala Glu Lys Asp Asn Ile
 65 70 75 80

Val Leu Gly Glu Gly Gly Ile Thr Leu Ser Gly Gly Gln Arg Ala Arg
 85 90 95

Ile Ser Leu Ala Arg Ala Val Tyr Lys Asp Ala Asp Leu Tyr Leu Leu
 100 105 110

Asp Ser Pro Phe Gly Tyr Leu Asp Val Leu Thr Glu Lys Glu Ile Phe
 115 120 125

Glu Ser Cys Val Cys Lys Leu Met Ala Asn Lys Thr Arg Ile Leu Val
 130 135 140

Thr Ser Lys Met Glu His Leu Lys Lys Ala Asp Lys Ile Leu Ile Leu
 145 150 155 160

His Glu Gly Ser Ser Tyr Phe Tyr Gly Thr Phe Ser Glu Leu Gln Asn
 165 170 175

Leu Gln Pro Asp Phe Ser Ser Lys Leu Met Gly Cys Asp Ser Phe

180

185

190

<210> 39

<211> 390

<212> PRT

<213> Homo sapiens

<400> 39

Lys Tyr Ile Glu His Phe Ser Lys Phe Ser Pro Ser Pro Leu Ser Met
 1 5 10 15

Lys Gln Phe Leu Asp Phe Gly Ser Ser Asn Ala Cys Glu Lys Thr Ser
 20 25 30

Phe Thr Phe Leu Arg Gln Glu Leu Pro Val Arg Leu Ala Asn Ile Met
 35 40 45

Lys Glu Ile Asn Leu Leu Pro Asp Arg Val Leu Ser Thr Pro Ser Val
 50 55 60

Gln Leu Val Gln Ser Trp Tyr Val Gln Ser Leu Leu Asp Ile Met Glu
 65 70 75 80

Phe Leu Asp Lys Asp Pro Glu Asp His Arg Thr Leu Ser Gln Phe Thr
 85 90 95

Asp Ala Leu Val Thr Ile Arg Asn Arg His Asn Asp Val Val Pro Thr
 100 105 110

Met Ala Gln Gly Val Leu Glu Tyr Lys Asp Thr Tyr Gly Asp Asp Pro
 115 120 125

Val Ser Asn Gln Asn Ile Gln Tyr Phe Leu Asp Arg Phe Tyr Leu Ser
 130 135 140

Arg Ile Ser Ile Arg Met Leu Ile Asn Gln His Thr Leu Ile Phe Asp
 145 150 155 160

Gly Ser Thr Asn Pro Ala His Pro Lys His Ile Gly Ser Ile Asp Pro
 165 170 175

Asn Cys Asn Val Ser Glu Val Val Lys Asp Ala Tyr Asp Met Ala Lys
 180 185 190

Leu Leu Cys Asp Lys Tyr Tyr Met Ala Ser Pro Asp Leu Glu Ile Gln
 195 200 205

Glu Ile Asn Ala Ala Asn Ser Lys Gln Pro Ile His Met Val Tyr Val
 210 215 220

Pro Ser His Leu Tyr His Met Leu Phe Glu Leu Phe Lys Asn Ala Met
 225 230 235 240

Arg Ala Thr Val Glu Ser His Glu Ser Ser Leu Ile Leu Pro Pro Ile
 245 250 255

Lys Val Met Val Ala Leu Gly Glu Glu Asp Leu Ser Ile Lys Met Ser
 260 265 270

Asp Arg Gly Gly Gly Val Pro Leu Arg Lys Ile Glu Arg Leu Phe Ser
 275 280 285

Tyr Met Tyr Ser Thr Ala Pro Thr Pro Gln Pro Gly Thr Gly Gly Thr
 290 295 300

Pro Leu Ala Gly Phe Gly Tyr Gly Leu Pro Ile Ser Arg Leu Tyr Ala
 305 310 315 320

Lys Tyr Phe Gln Gly Asp Leu Gln Leu Phe Ser Met Glu Gly Phe Gly
 325 330 335

Thr Asp Ala Val Ile Tyr Leu Lys Ala Leu Ser Thr Asp Ser Val Glu
 340 345 350

Arg Leu Pro Val Tyr Asn Lys Ser Ala Trp Arg His Tyr Gln Thr Ile
 355 360 365

Gln Glu Ala Gly Asp Trp Cys Val Pro Ser Thr Glu Pro Lys Asn Thr
 370 375 380

Ser Thr Tyr Arg Val Ser
 385 390

<210> 40

<211> 202

<212> PRT

<213> Bacillus licheniformis

<400> 40

Ser Phe Ser Glu Leu Asn Ile Asp Ala Phe Arg Phe Ile Asn Asp Leu
 1 5 10 15

Gly Lys Glu Tyr Ser Met Leu Asn Pro Val Val Tyr Phe Leu Ala Glu
 20 25 30

Tyr Met Met Tyr Phe Leu Ala Leu Gly Leu Val Val Tyr Trp Leu Thr
 35 40 45

Arg Thr Thr Lys Asn Arg Leu Met Val Ile Tyr Ala Val Ile Ala Phe
 50 55 60

Val Val Ala Glu Ile Leu Gly Lys Ile Met Gly Ser Leu His Ser Asn
 65 70 75 80

Tyr Gln Pro Phe Ala Thr Leu Pro Asn Val Asn Lys Leu Ile Glu His
 85 90 95

Glu Ile Asp Asn Ser Phe Pro Ser Asp His Thr Ile Leu Phe Phe Ser
 100 105 110

Ile Gly Phe Leu Ile Phe Leu Phe His Lys Lys Thr Gly Trp Leu Trp
 115 120 125

Leu Val Leu Ala Phe Ala Val Gly Ile Ser Arg Ile Trp Ser Gly Val
 130 135 140

His Tyr Pro Leu Asp Val Ala Ala Gly Ala Leu Leu Gly Val Leu Ser
 145 150 155 160

Ala Leu Phe Val Phe Trp Thr Ala Pro Lys Leu Ser Phe Ile His Gln
 165 170 175

Met Leu Ser Leu Tyr Glu Lys Val Glu Gln Arg Ile Val Pro Ser Lys
 180 185 190

Asn Lys Ser Asn Asp Lys Ser Lys Asn Phe
 195 200

<210> 41

<211> 354

<212> PRT

<213> Homo sapiens

<400> 41

Gln Arg Ser Pro Leu Glu Lys Ala Ser Val Val Ser Lys Leu Phe Phe
 1 5 10 15

Ser Trp Thr Arg Pro Ile Leu Arg Lys Gly Tyr Arg Gln Arg Leu Glu
 20 25 30

Leu Ser Asp Ile Tyr Gln Ile Pro Ser Val Asp Ser Ala Asp Asn Leu
 35 40 45

Ser Glu Lys Leu Glu Arg Glu Trp Asp Arg Glu Leu Ala Ser Lys Lys
 50 55 60

Asn Pro Lys Leu Ile Asn Ala Leu Arg Arg Cys Phe Phe Trp Arg Phe
 65 70 75 80

Met Phe Tyr Gly Ile Phe Leu Tyr Leu Gly Glu Val Thr Lys Ala Val
 85 90 95

Gln Pro Leu Leu Leu Gly Arg Ile Ile Ala Ser Tyr Asp Pro Asp Asn
 100 105 110

Lys Glu Glu Arg Ser Ile Ala Ile Tyr Leu Gly Ile Gly Leu Cys Leu
 115 120 125

Leu Phe Ile Val Arg Thr Leu Leu Leu His Pro Ala Ile Phe Gly Leu
 130 135 140

His His Ile Gly Met Gln Met Arg Ile Ala Met Phe Ser Leu Ile Tyr
 145 150 155 160

Lys Lys Thr Leu Lys Leu Ser Ser Arg Val Leu Asp Lys Ile Ser Ile
 165 170 175

Gly Gln Leu Val Ser Leu Leu Ser Asn Asn Leu Asn Lys Phe Asp Glu
 180 185 190

Gly Leu Ala Leu Ala His Phe Val Trp Ile Ala Pro Leu Gln Val Ala
 195 200 205

Leu Leu Met Gly Leu Ile Trp Glu Leu Leu Gln Ala Ser Ala Phe Cys
 210 215 220

Gly Leu Gly Phe Leu Ile Val Leu Ala Leu Phe Gln Ala Gly Leu Gly
 225 230 235 240

Arg Met Met Met Lys Tyr Arg Asp Gln Arg Ala Gly Lys Ile Ser Glu
 245 250 255

Arg Leu Val Ile Thr Ser Glu Met Ile Glu Asn Ile Gln Ser Val Lys
 260 265 270

Ala Tyr Cys Trp Glu Glu Ala Met Glu Lys Met Ile Glu Asn Leu Arg
 275 280 285

Gln Thr Glu Leu Lys Leu Thr Arg Lys Ala Ala Tyr Val Arg Tyr Phe
 290 295 300

Asn Ser Ser Ala Phe Phe Phe Ser Gly Phe Phe Val Val Phe Leu Ser
 305 310 315 320

Val Leu Pro Tyr Ala Leu Ile Lys Gly Ile Ile Leu Arg Lys Ile Phe
 325 330 335

Thr Thr Ile Ser Phe Cys Ile Val Leu Arg Met Ala Val Thr Arg Gln
 340 345 350

Phe Pro

<210> 42

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 42

tttttggatc caattccaat ggatgggtcat ggag

34

<210> 43

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 43
aaggatccaa gcttcaaggt ttaggctttg aattattgtc c 41

<210> 44
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide
<400> 44
tttttggatc caatgctttt ggtggaggga aaaatc 36

<210> 45
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide
<400> 45
ctcagcgggtg gcagcagcc 19

<210> 46
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide
<400> 46
cgcggtatccc atggggacaa taattcaaag c 31

<210> 47
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide
<400> 47
ggcgaattca cgcgttaaaa taataatttc tggctcac 38

<210> 48

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 48

ccgggggtacc aatttggtga atttocacag aatgatc

37

<210> 49

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 49

ggcgaattca cgcgttagca acgaggggtg ctccc

35

<210> 50

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 50

cgcggatccg cagacgtggc tggcgcc

27

<210> 51

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 51

ggcgaattca cgcgttaagc ttgctcacg tgagtttc

38

<210> 52

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 52

cgcggtaccc ctaatggtga tgacagcctc

30

<210> 53

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 53

ggcgaattca cgcgttagaa agaatcacat cccatgag

38

<210> 54

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 54

ccgggggtacc aagtacatag agcacttcag caagttc

37

<210> 55

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 55

ggcgaattca cgcgttacgt gacgcggtac gtgggtcg

37

<210> 56

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 56

cgcggtatcct ttccagaatt aaatattgat g

31

<210> 57

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 57

ggcgaattca cgcgttaaaa gttcttcgat ttatcg

36

<210> 58

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 58

cgcggtatccc agaggtcgcc tctgg

25

<210> 59

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 59

ggcgaattca cgcgttaggg aaattgccga gtgac

35

<210> 60

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 60

tttttttaggc cttctcagag caaccgggag

30

<210> 61

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 61

ttttacgcgt tcatttccga ctgaagag

28

(19) World Intellectual Property
Organization
International Bureau



09 JUL 2004



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 2003/057708 A3

(51) International Patent Classification⁷: **C12N 15/62**,
C07K 14/245, 14/47, C12N 1/00, 5/00, 15/67, C07K 1/22,
G01N 33/68

(74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16
Theobalds Road, London WC1X 8PL (GB).

(21) International Application Number:
PCT/GB2003/000078

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 10 January 2003 (10.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0200689.8 10 January 2002 (10.01.2002) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): NEW-
CASTLE UNIVERSITY VENTURES LIMITED
[GB/GB]; Central Square South, Orchard Street, Newcas-
tle Upon Tyne, NE1 3XX (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GOKCE, Isa
[TR/TR]; Gaziosmanpasa Universitesi, Fen Edebiyat
Fakultesi Kimya Bolumu, 60240 Tokat (TR). ANDER-
LUH, Gregor [SI/SI]; Department of Biology, Biotechni-
cal Faculty, University of Ljubljana, Vecna pot 111, 1000
Ljubljana (SI). LAKEY, Jeremy, Hugh [GB/GB]; School
of Cell and Molecular Biosciences, The Medical School,
The University of Newcastle-upon-Tyne NE2 4HH (GB).

(88) Date of publication of the international search report:
31 December 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: FUSION PROTEINS

(57) Abstract: The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or pu-
rification systems. The present inventors have found that the To1AIII domain has remarkable properties which are of particular use
as a fusion protein partner to achieve high levels of expression in a host cell. In one aspect of the invention, a To1AIII domain or a
functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and a non-To1A
polypeptide is located towards the C-terminus of the fusion polypeptide.

WO 2003/057708 A3

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB 02/00078

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	C12N15/62 C12N15/67	C07K14/245 C07K1/22
C07K14/47 G01N33/68	C12N1/00	C12N5/00
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) MEDLINE, BIOSIS, EPO-Internal, WPI Data, PAJ, EMBASE, CHEM ABS Data, LIFESCIENCES SCISEARCH, BIOTECHNOLOGY ABS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RIECHMANN LUTZ ET AL: "The C-terminal domain of TolA is the coreceptor for filamentous phage infection of E. coli." CELL, vol. 90, no. 2, 1997, pages 351-360, XP001154544 ISSN: 0092-8674 abstract page 353 page 358 figure 3	1-36
Y	WO 01 21817 A (MUYLDERMANS SERGE ;VLAAMS INTERUNIVERSITAIR INST (BE); SILENCE KAR) 29 March 2001 (2001-03-29) page 7, line 11 - line 13 page 7, line 26 -page 8, line 8 page 36, line 1 - line 7	1-36
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but... later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search 8 October 2003		Date of mailing of the international search report 22/10/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Surdej, P

INTERNATIONAL SEARCH REPORT

 International Application No.
 PCT/GB 92/00078

C.(Continuation) DOCUMENTS CONSIDERED RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LUBKOWSKI JACEK ET AL: "Filamentous phage infection: Crystal structure of g3p in complex with its coreceptor, the C-terminal domain of TolA." STRUCTURE (LONDON), vol. 7, no. 6, June 1999 (1999-06), pages 711-722, XP002254019 ISSN: 0969-2126 abstract page 711 - page 713</p> <p>---</p>	1-36
Y	<p>DEROUICHE RAHMONA ET AL: "Binding of colicins A and E1 to purified TolA domains." MICROBIOLOGY (READING), vol. 143, no. 10, 1997, pages 3185-3192, XP001154659 ISSN: 1350-0872 abstract page 3187 figure 1 table 1 page 3190</p> <p>---</p>	1-36
Y	<p>WAN ET AL: "TolAIII co-overexpression facilitates the recovery of periplasmic recombinant proteins into the growth medium of Escherichia coli" PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, US, vol. 14, no. 1, October 1998 (1998-10), pages 13-22, XP000864465 ISSN: 1046-5928 page 18 - page 20 figures 4-6</p> <p>---</p>	1-36
Y	<p>EP 0 299 810 A (INST NAT SANTE RECH MED ;CENTRE NAT RECH SCIENT (FR); PASTEUR INST) 18 January 1989 (1989-01-18) page 1 - page 2</p> <p>---</p>	1-36
Y	<p>LAVALLIE E R ET AL: "A THIOREDOXIN GENE FUSION EXPRESSION SYSTEM THAT CIRCUMVENTS INCLUSION BODY FORMATION IN THE E. COLI CYTOPLASM" BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 11, no. 2, February 1993 (1993-02), pages 187-193, XP002102990 ISSN: 0733-222X abstract</p> <p>---</p>	1-36
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 02/00078

C.(Continuation) DOCUMENTS CONSIDERED RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DEPREZ CHRISTOPHE ET AL: "Macromolecular import into Escherichia coli: the TolA C-terminal domain changes conformation when interacting with the colicin A toxin." BIOCHEMISTRY. UNITED STATES 26 FEB 2002, vol. 41, no. 8, 26 February 2002 (2002-02-26), pages 2589-2598, XP002254021 ISSN: 0006-2960 abstract page 2589 -page 2590 ---	1-36
P,Y	WALBURGER ANNE ET AL: "The Tol/Pal system function requires an interaction between the C-terminal domain of TolA and the N-terminal domain of TolB." MOLECULAR MICROBIOLOGY, vol. 44, no. 3, May 2002 (2002-05), pages 695-708, XP002254022 May, 2002 ISSN: 0950-382X page 698 -page 700 ---	1-36
T	ANDERLUH GREGOR ET AL: "Expression of proteins using the third domain of the Escherichia coli periplasmic-protein TolA as a fusion partner." PROTEIN EXPRESSION AND PURIFICATION, vol. 28, no. 1, 20 March 2003 (2003-03-20), pages 173-181, XP002254023 ISSN: 1046-5928 the whole document -----	1-36

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 02/00078

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0121817	A	29-03-2001	EP 1088892 A1 04-04-2001
		AU 7780300 A	24-04-2001
		CA 2385664 A1	29-03-2001
		WO 0121817 A1	29-03-2001
		EP 1214430 A1	19-06-2002
		US 2003165877 A1	04-09-2003
		US 2003148508 A1	07-08-2003
		US 6479280 B1	12-11-2002
EP 0299810	A	18-01-1989	FR 2615528 A1 25-11-1988
		DK 19889 A	17-01-1989
		EP 0299810 A1	18-01-1989
		WO 8809375 A1	01-12-1988
		JP 2500640 T	08-03-1990
		PT 87505 A , B	31-05-1989

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.